Newsletter Archive
-
02.21.24 -- The RNA Therapeutics Supply Chain: A Platform Of Relationships
2/21/2024
02/21/24 Advancing RNA Newsletter
-
02.14.24 -- The Game Of RISK Meets mRNA
2/14/2024
02/14/24 Advancing RNA Newsletter
-
02.07.24 -- From "Barbieland" To ATW 2024: Evolving Beyond "Stereotypical" ATMPs
2/7/2024
02/07/24 Advancing RNA Newsletter
-
01.31.24 -- Why Nike's "Just Do It!" Is The Wrong Slogan For The RNA Industry
1/31/2024
01/31/24 Advancing RNA Newsletter
-
01.24.24 -- A Meditation On mRNA's Regulatory & Reputation Complexities
1/24/2024
01/24/24 Advancing RNA Newsletter
-
01.22.24 -- Enabling Capabilities And Solutions For All mRNA (Nucleic Acid) Platforms
1/22/2024
01/22/24 Advancing RNA Newsletter
-
01.17.24 -- How To Break RNA's "4-Minute Mile"
1/17/2024
01/17/24 Advancing RNA Newsletter
-
01.10.24 -- CQAs For mRNA/LNPs: Current & Future Considerations
1/10/2024
01/10/24 Advancing RNA Newsletter
-
01.03.24 -- Defining A Competitive Next-Gen RNA Therapeutic
1/3/2024
01/03/24 Advancing RNA Newsletter
-
12.20.23 -- Peter Marks: An Early Preview Of mRNA, Gene Therapy Platforms
12/20/2023
12/20/23 Advancing RNA Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more